Clinical trial Recruiting at 1 site Observational

Predicting outcomes and guiding antiplatelet treatment after PCI for people at high bleeding risk

Official title: Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol

Run by West China Hospital · NCT05369442 · Data updated 2026-11-12

This project uses medical records and AI to see what predicts worse outcomes and which antiplatelet medicines and treatment lengths are used in adults who had PCI and are at high risk of bleeding.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
SexAll
Enrollment1300 (estimated)
SponsorWest China Hospital
Academic / other
Locations1 site (Sichuan, Sichuan)
StatusRecruiting
StartedMay 1, 2022
Main results expectedMay 1, 2028
Study endsAugust 1, 2029
Registry record updatedJanuary 6, 2026
Trial IDNCT05369442 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (>18) who underwent PCI and meet ARC-HBR criteria (one major or two minor criteria) such as chronic oral anticoagulation, severe CKD, low hemoglobin, recent serious bleeding, thrombocytopenia, active malignancy, or recent intracranial hemorrhage.

Probably not a fit

Patients without high bleeding risk after PCI, those under 18, or individuals who cannot attend follow-up at the enrolling center are unlikely to benefit from this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center prospective registry at West China Hospital combines retrospective data extraction with prospective database building to collect detailed clinical, laboratory, imaging, and follow-up data on patients who had PCI and meet ARC-HBR criteria. Investigators will apply artificial intelligence methods to identify adverse prognostic predictors and to catalog the types and durations of antiplatelet regimens used in these high-bleeding-risk patients. The registry will compare safety and feasibility signals across different antiplatelet strategies and DAPT durations using real-time event monitoring and standardized outcome records. The collected data aim to refine existing bleeding prediction models and to inform more personalized antiplatelet decisions for PCI patients with high bleeding risk.

Why it matters

Potential benefit: If successful, the project could help personalize antiplatelet therapy to reduce bleeding and improve survival after PCI in patients at high bleeding risk.

How similar studies have gone: Previous randomized trials and registries have shown that shorter or alternative antiplatelet regimens can reduce bleeding without substantially increasing ischemic events in selected HBR populations, but AI-driven prognostic modeling and comprehensive real-world catalogs of regimen use remain relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

PCI patients \>18 years of age and meeting 1 major criterion or 2 minor criteria of the ARC-HBR The ARC-HBR major criteria included:

* long-term use of oral anticoagulants;
* severe or end-stage chronic kidney disease \[eGFR \<30 ml/(min\*1.73m2 )\];
* hemoglobin \<11 g/dl, spontaneous bleeding requiring hospitalization or transfusion within the past 6 months or at any time;
* chronic bleeding constitutional;
* cirrhosis with portal hypertension spontaneous bleeding requiring hospitalization or transfusion within the past 6 months or at any time;
* moderate to severe baseline thrombocytopenia (platelets \<100×10\^9/L); chronic bleeding constitutional;
* cirrhosis with portal hypertension;
* active malignancy within the past 12 months (excluding non-melanoma skin cancer);
* previous spontaneous brain hemorrhage (at any time);
* traumatic brain hemorrhage within the past 12 months;
* within the past 6 months moderate or severe ischemic stroke within the past 6 months;
* the presence of cerebral arteriovenous malformation;
* recent major surgery or major trauma within 30 days prior to PCI;
* and major non-delayable surgery during DAPT.

Secondary criteria included:

* age ≥75 years;
* moderate chronic kidney disease \[30 ml/(min\*1.73m2 ) ≤ eGFR ≤ 59 ml/(min\*1.73m2 )\];
* 11 g/dl ≤ hemoglobin \< 13 g/dl in men and 11 g/dl ≤ hemoglobin \< 12 g/dl in women; - spontaneous bleeding requiring hospitalization or blood transfusion in the past 6 months to 12 months;
* long-term use of oral NSAIDs or steroids
* Ischemic stroke of any duration not covered by the primary criteria.

Exclusion Criteria:

* Patients who were already bleeding at the time of baseline inclusion
* Patients who could not be followed up (including previously reserved phone changes, etc.) to obtain MACE events.

Where it's running

  • West China Hospital, Sichuan University
    Sichuan, Sichuan, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.